Antibodies and Transplantation: All the Information One Could Ever Want

Introduction:

Antibodies are defensively produced by the immune system against germs and viruses. Antibodies are beneficial in transplantation when they are prepared to fight foreign invaders that may cause disease. However, they can also be prepared to fight foreign tissue, like a newly transplanted kidney. Antibodies against various tissue types, also referred to as donor-specific antibodies (anti-HLA DSAs), against human leukocyte antigens are therefore evaluated before donation. Suppose one received a transplant from a particular kidney donor. In that case, they may be at a higher risk of rejection if they have high antibodies directed against distinct tissue types. The crossmatch will probably be positive (reactive) if there are antibodies against the specific kidney donor they received, which increases the likelihood of transplant rejection.

What Are Antibodies?

Antibodies, proteins generated by the immune system, guard the body against foreign substances. They attach themselves to these foreign chemicals and drive them out of the body. An antibody is also known as immunoglobulin.

B cells are specialized white blood cells that manufacture antibodies. B cells proliferate and clone when they come into touch with an antigen. The lymphatic and circulatory systems receive millions of antibodies from these cloned B cells, also known as plasma cells.

The body has antibodies in many places, including the skin, lungs, tears, saliva, and even breast milk. In actuality, colostrum—a viscous fluid released by the breasts for a few days following childbirth—contains a significant concentration of antibodies. For this reason, nursing has been shown to strengthen a baby's immune system.

What Is Antibody-Mediated Rejection?

All allograft rejection resulting from antibodies directed against donor-specific HLA molecules, blood group antigen (ABO)-isoagglutinin, or endothelial cell antigens are referred to as antibody-mediated rejection (AMR).

Antibody-mediated rejection can be a difficult procedure that responds poorly to treatment and has a dire outlook for the graft. Treatment protocols for antimicrobial resistance (AMR) align with these perspectives by employing variations of a multifaceted strategy that comprises four main components:

1. Naive and memory B-cell depletion.

2. Donor reactive antibody removal.

3. Blockade of the residual alloantibody.

4. Suppression of the T-cell-dependent antibody response.

What Is the Classification of Antibody-Mediated Damage?

1. Hyperacute Rejection: A few minutes after the transplant, when the antigens are mismatched, hyperacute rejection happens. To save the recipient's life, the tissue must be removed immediately. When a receiver receives the incorrect blood type, they experience this kind of rejection. For instance, when someone type B is given type A blood.

2. Acute Antibody-Mediated Rejection: Typically as a result of antibodies produced after transplantation. From the first week following the transplant to three months later, acute rejection can happen at any time. There is some acute rejection experienced by each receiver.

3. Chronic Antibody-Mediated Rejection: Chronic rejection can occur over an extended period. The transplanted tissues or organs gradually deteriorate due to the body's ongoing immunological reaction to the new organ.

How Can Antibody-Mediated Rejection of Kidneys Be Diagnosed?

1. Single-Antigen Bead Test: In the present methods, this is the last step in identifying antibodies that potentially harm the allograft and is utilized to detect anti-HLA antibodies. It is presently employed as a diagnostic tool for AMR and to monitor transplant patients.

2. Complement-Dependent Cytotoxicity: Complement-dependent cytotoxicity (CDC) is still the gold standard for detecting premade antibodies. This immunological response causes target cells to lyse by activating and attracting the complement cascade to the targeted cell surface.

3. Electron Microscopy: Transplant patients frequently have their biopsies performed using electron microscopy because light microscopy cannot always identify early alterations.

How Are Antibody-Mediated Rejection of Kidneys Treated?

1. Plasmapheresis: A procedure called plasmapheresis is used to filter blood and get rid of dangerous antibodies. It is a process carried out similarly to dialysis, except it selectively eliminates antibodies from the blood's plasma. Before transplant, plasmapheresis eliminates the recipient's antibodies against the donor blood type, protecting the donated kidney from harm. An injectable medication to prevent the formation of new antibodies may also be used, depending on the antibody levels and transplant center policies.

2. Immunoglobulin Therapy: As part of a protocol, these highly sensitized patients receive a large dose of intravenous immunoglobulin, or IVIG, along with additional drugs. As a result of the IVIG infusions, patients awaiting transplants have fewer organ-rejecting antibodies, which may be repeated over months.

3. Eculizumab: Eculizumab is a long-acting humanized monoclonal antibody that targets complement C5. It prevents C5 from being cleaved into C5a and C5b, preventing the terminal complement system from being deployed and creating MAC. Eculizumab significantly decreases hemolysis in PNH patients.

4. Proteasome Inhibitor: The idea behind proteasome inhibitor (PI) therapy for antigen-producing plasma cells (AMR) is to eliminate them. PLEX, IVIG, or rituximab have all been tried in conjunction with Bosentasomib, which is presently licensed to treat multiple myeloma as a rescue therapy for AMR, with some promising outcomes.

5. Complement Inhibition: The FDA has approved two medicines for complement suppression: Eculizumab, an anti-C5 monoclonal antibody, and C1-INH, a C1 esterase inhibitor. Eculizumab has been approved for the treatment of atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria. Patients with hereditary angioedema are permitted to utilize C1-INH.

How Can the Kidney Antibody-Mediated Rejection Be Prevented?

While high-dose intravenous immunoglobulin and plasmapheresis have successfully prevented and treated antimicrobial resistance (AMR), irreparable damage, such as transplant glomerulopathy, can sometimes show symptoms months or even years after the initial injury. Improving the results for patients at risk for antimicrobial resistance (AMR) is an unfulfilled need.

Conclusion:

The immune system naturally produces antibodies as a defense against germs and viruses. When antibodies are prepared to fight foreign invaders that can cause disease, they are beneficial in the setting of transplantation, but they can also be prepared to fight foreign tissue, such as a newly transplanted kidney. This is why donor-specific antibodies, or anti-human leukocyte antigens (HLA DSAs), against various tissue types are evaluated before donation. If one has a kidney transplant from a particular donor, a high level of antibodies against various tissue types could mean they are more likely to be rejected.